Raynaud's Phenomenon Diagnosis and Management

Diagnostic Approach

• Raynaud's phenomenon is diagnosed clinically based on episodic vasospasm of digital arteries causing color changes triggered by cold exposure or emotional stress, with the critical distinction being between primary and secondary forms 1, 2
• Primary Raynaud's is characterized by isolated vasospastic attacks without underlying disease 1
• Secondary Raynaud's is associated with underlying connective tissue disease, most commonly systemic sclerosis 1, 2

Clinical Criteria for Diagnosis

• Primary Raynaud's typically affects individual digits rather than entire hand 2
• Secondary Raynaud's may involve entire hand rather than just individual digits 2, 3
• Severe, painful episodes with potential for digital ulcers, gangrene, or osteomyelitis are characteristic of secondary Raynaud's 1, 2

Key Physical Examination Findings

• Joint deformities, splinter hemorrhages under nails, scleroderma changes, facial rosacea, and seborrhea are key findings 4
• Digital examination may reveal ulcers, tissue necrosis, or gangrene 1, 2

Laboratory Evaluation

• Anti-Sjögren syndrome A antibody testing is recommended if dry eyes or mouth are present 4
• Viral serology, including HBV, HCV, and HIV, is recommended if systemic disease is suspected 5
• Prothrombotic workup, including protein C, protein S, antithrombin III, Factor V Leiden, prothrombin mutations, lupus anticoagulant, and anticardiolipin antibody, is recommended if vascular thrombosis is suspected 1, 2

Treatment Algorithm

• Cold avoidance, smoking cessation, and avoidance of triggers are first-line non-pharmacological management strategies for all patients 1, 3
• Nifedipine or other dihydropyridine calcium channel blockers are first-line pharmacotherapy for primary and secondary Raynaud's 6, 1
• Phosphodiesterase-5 inhibitors, such as sildenafil or tadalafil, are effective for both attacks and digital ulcer healing/prevention in secondary Raynaud's 6, 1
• Intravenous iloprost is recommended for severe Raynaud's unresponsive to oral therapies 6, 1
• Bosentan, an endothelin receptor antagonist, prevents new digital ulcers but does not improve healing 6, 1

Common Pitfalls

• Missing secondary causes, such as systemic sclerosis, can lead to delayed treatment and poor outcomes 1, 2
• Delaying treatment in secondary Raynaud's can result in digital ulcers and other complications 2
• Using beta-blockers, ergot alkaloids, bleomycin, or clonidine can induce or worsen Raynaud's 1, 2

Monitoring and Follow-up

• Regular monitoring for digital ulcers, gangrene, and progression of underlying disease is recommended for secondary Raynaud's 3
• Reassessing treatment efficacy at 3-6 months and escalating therapy if inadequate response is recommended 6

Management of Secondary Raynaud's Phenomenon

Non-Pharmacological Management

• The European League Against Rheumatism (EULAR) recommends cold avoidance with proper warm clothing, including mittens, hat, and insulated footwear, for patients with Raynaud's phenomenon, particularly those with systemic sclerosis and lupus 7, 8
• Use of gloves and heating devices for hands is advised for patients with Raynaud's phenomenon, as recommended by EULAR 7, 9
• Avoidance of direct contact with cold surfaces and thorough skin drying is recommended for patients with Raynaud's phenomenon, as part of non-pharmacological management 7, 8
• Smoking cessation is recommended for patients with Raynaud's phenomenon, as part of non-pharmacological management 10
• Physical exercise should be considered for both systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) patients with Raynaud's phenomenon, as recommended by EULAR 7, 8

Multidisciplinary Collaboration

• The European League Against Rheumatism (EULAR) emphasizes the need for specialized training for providers of non-pharmacological management of Raynaud's phenomenon, particularly for patients with SLE and SSc 7, 9, 8
• Regular training for providers of non-pharmacological management is advised, as recommended by EULAR 9, 8
• Educational programs within EULAR dedicated to management of SLE and SSc are advocated, as part of multidisciplinary collaboration 9, 8
• Patient education and self-management support should be considered for improving hand function and quality of life, as recommended by EULAR 9, 8

Evaluation and Management of Secondary Raynaud’s Phenomenon

Clinical Indicators Suggesting Secondary Disease

• Dysphagia or gastro‑esophageal reflux should prompt evaluation for an underlying connective‑tissue disease, particularly systemic sclerosis. 11
• The presence of digital ulcers or gangrene is common in systemic sclerosis (≈50 % develop ulcers and ≈22 % develop gangrene). Early recognition is essential for preventing severe complications. [11][12]
• Patients with isolated Raynaud’s who have abnormal nailfold capillaroscopy or disease‑specific autoantibodies have a ≈50 % risk of progressing to a defined connective‑tissue disease during long‑term follow‑up. 11

Diagnostic Testing

First‑Tier Screening

• Antinuclear antibody (ANA) testing is the primary laboratory screen for connective‑tissue disease in all patients with suspected secondary Raynaud’s. 11
• Nailfold capillaroscopy that reveals dilated loops, hemorrhages, or avascular areas strongly predicts an underlying connective‑tissue disease, especially systemic sclerosis. 13

Second‑Tier Serologic Evaluation

• Anti‑RNA polymerase III antibodies identify patients with diffuse systemic sclerosis who are at increased risk for renal crisis. 11
• Comprehensive thrombophilia panels—including protein C, protein S, antithrombin III, Factor V Leiden, prothrombin gene mutation, lupus anticoagulant, anticardiolipin antibodies, and homocysteine level—should be ordered when a pro‑thrombotic etiology is suspected. 14

Etiologic and Risk Factors

• Beta‑blocker therapy is a frequent iatrogenic cause of Raynaud’s symptoms and should be reviewed before extensive work‑up. 14
• Ergot alkaloids, bleomycin, and clonidine can induce or exacerbate Raynaud’s phenomena; medication review is mandatory. [14][12]
• Pro‑thrombotic states (e.g., protein C/S deficiency, Factor V Leiden, antiphospholipid syndrome) may manifest as Raynaud’s and require anticoagulation strategies distinct from standard vasodilator therapy. 14

Prognostic Implications

• Systemic sclerosis remains the most common connective‑tissue disease associated with secondary Raynaud’s; early detection via ANA, disease‑specific antibodies, and capillaroscopy is critical for reducing morbidity. [14][11]13
• Because connective‑tissue disease may not become clinically apparent for years after Raynaud’s onset, a minimum two‑year observation period is recommended before confirming a primary Raynaud’s diagnosis. 13